Jun 2 2011![NewsGuard 100/100 Score](https://d2jx2rerrg6sh3.cloudfront.net/images/newsguard-100.svg)
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that the U.S. Food and Drug Administration has granted approval for the Company's Abbreviated New Drug Application (ANDA) to market a generic version of Eisai's Alzheimer's treatment Aricept® (Donepezil Hydrochloride) Tablets, 5 mg and 10 mg. Shipment of this product has commenced.
Annual sales of the product, including brand and generic sales, were approximately $2.3 billion in the United States, based on IMS sales data.
Source:
Teva Pharmaceutical Industries Ltd.